Pharmacoepidemiology in the Era of Real-World Evidence

Pharmacoepidemiology in the Era of Real-World Evidence Curr Epidemiol Rep (2017) 4:262–265 https://doi.org/10.1007/s40471-017-0123-y INVITED COMMENTARY Sengwee Toh Published online: 19 October 2017 Springer International Publishing AG 2017 Long before the terms real-world data (RWD) and real-world [7]. In other words, RWE generated from observational stud- evidence (RWE) were coined, researchers had been using data ies or pragmatic trials that leverage routinely collected elec- collected as part of routine healthcare delivery to generate tronic health data may soon be used to supplement findings evidence about the utilization, benefits, and risks of medical from traditional randomized controlled trials in the approval of medical products [8, 9]. Safety findings from post- products [1–4]. There are several variations to the definitions of RWD and RWE, but most are similar to the ones used by marketing RWD-based studies, which have been more formal- the US Food and Drug Administration (FDA), which defines ly integrated into regulatory review in the USA recently [10], RWD as “data relating to patient health status and/or the de- maygainadditional regulatory importance. livery of health care routinely collected from a variety of It will be interesting to see how regulatory agencies and the sources” and RWE as “the clinical evidence regarding the research community react and position http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Epidemiology Reports Springer Journals

Pharmacoepidemiology in the Era of Real-World Evidence

Loading next page...
 
/lp/springer_journal/pharmacoepidemiology-in-the-era-of-real-world-evidence-x8OLRD7w7i
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Epidemiology
eISSN
2196-2995
D.O.I.
10.1007/s40471-017-0123-y
Publisher site
See Article on Publisher Site

Abstract

Curr Epidemiol Rep (2017) 4:262–265 https://doi.org/10.1007/s40471-017-0123-y INVITED COMMENTARY Sengwee Toh Published online: 19 October 2017 Springer International Publishing AG 2017 Long before the terms real-world data (RWD) and real-world [7]. In other words, RWE generated from observational stud- evidence (RWE) were coined, researchers had been using data ies or pragmatic trials that leverage routinely collected elec- collected as part of routine healthcare delivery to generate tronic health data may soon be used to supplement findings evidence about the utilization, benefits, and risks of medical from traditional randomized controlled trials in the approval of medical products [8, 9]. Safety findings from post- products [1–4]. There are several variations to the definitions of RWD and RWE, but most are similar to the ones used by marketing RWD-based studies, which have been more formal- the US Food and Drug Administration (FDA), which defines ly integrated into regulatory review in the USA recently [10], RWD as “data relating to patient health status and/or the de- maygainadditional regulatory importance. livery of health care routinely collected from a variety of It will be interesting to see how regulatory agencies and the sources” and RWE as “the clinical evidence regarding the research community react and position

Journal

Current Epidemiology ReportsSpringer Journals

Published: Oct 19, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off